Our Venture Fund on the search for groundbreaking trends Our Venture Fund on the search for groundbreaking trends The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Purevax range now available in 0.5 ml presentation Purevax range now available in 0.5 ml presentation Boehringer Ingelheim announces reduced volume 0.5 ml Purevax vaccines for cats, more convenient vaccination experience combined with same efficacy
Aservo EquiHaler wins Red Dot 2020 for design quality Aservo EquiHaler wins Red Dot 2020 for design quality Aservo EquiHaler wins a prestigious Red Dot Award 2020 for outstanding design quality
TwistPak Mixing platform for swine vaccines TwistPak Mixing platform for swine vaccines TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
Inauguration of new integrated Asian Veterinary R&D Center in China Inauguration of new integrated Asian Veterinary R&D Center in China Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center
The impact of carbon reduction projects The impact of carbon reduction projects Boehringer Ingelheim voluntarily contributes to carbon reduction projects that benefit sustainable development.
Targeting HER2 in cancer: The story of zongertinib Targeting HER2 in cancer: The story of zongertinib We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
1885-1948: Innovative beginnings 1885-1948: Innovative beginnings The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
Dogs at work in Milan offices Dogs at work in Milan offices Dogs at work is a pilot project that allows pet-lover to bring their dogs to the office and enjoy the benefits they bring to their daily work life.
Boehringer Ingelheim advances SIRP immune-oncology program Boehringer Ingelheim advances SIRP immune-oncology program Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Ethical Business Practices Ethical Business Practices Suppliers shall conduct their business in an ethical manner and act with integrity.
Innovation in medicinal chemistry Innovation in medicinal chemistry Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
The impact of A Life in a Day of a patient The impact of A Life in a Day of a patient A Life in a Day disease simulations are opening our eyes to the patient experience, exposing a surprising knowledge gap and driving change.
License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies
SPEVIGO approved expanded indications China US SPEVIGO approved expanded indications China US SPEVIGO® approved for expanded indications in China and the US